Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for BVNRY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 -36.42M
March 31, 2026 -36.14M
December 31, 2025 -1.648M
September 30, 2025 9.452M
June 30, 2025 -2.450M
March 31, 2025 -22.71M
December 31, 2024 -2.428M
September 30, 2024 15.95M
June 30, 2024 -3.829M
March 31, 2024 -1.562M
December 31, 2023 0.5046M
September 30, 2023 -1.270M
June 30, 2023 22.61M
March 31, 2023 84.22M
December 31, 2022 31.20M
September 30, 2022 13.69M
June 30, 2022 32.90M
March 31, 2022 11.37M
December 31, 2021 296.13M
September 30, 2021 30.87M
June 30, 2021 49.99M
March 31, 2021 185.62M
December 31, 2020 3.421M
September 30, 2020 0.7753M
June 30, 2020 -1.485M
Date Value
March 31, 2020 200.98M
December 31, 2019 205.13M
September 30, 2019 0.9544M
June 30, 2019 -0.8428M
March 31, 2019 -38.14M
December 31, 2018 -1.556M
September 30, 2018 -7.050M
June 30, 2018 29.31M
March 31, 2018 18.21M
December 31, 2017 61.92M
September 30, 2017 30.45M
June 30, 2017 -0.2183M
March 31, 2017 0.868M
December 31, 2016 3.673M
September 30, 2016 -0.3845M
June 30, 2016 94.06M
March 31, 2016 0.2979M
December 31, 2015 1.488M
September 30, 2015 0.2037M
June 30, 2015 0.5682M
March 31, 2015 1.690M
December 31, 2014 39.26M
September 30, 2014 -0.3961M
June 30, 2014 -0.0001M
March 31, 2014 -0.3856M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Evaxion AS --
Genmab A/S -74.60M
Ascendis Pharma A/S -53.34M
Zealand Pharma A/S -67.67M
Agenus, Inc. 14.68M